NCT05232006View on ClinicalTrials.gov

PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

May 31, 2030

Conditions
Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers
Interventions
DRUG

Niraparib

Niraparib, once daily

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT05232006 - PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers | Biotech Hunter | Biotech Hunter